NFE2L1 — Nuclear Factor Erythroid 2-Like 1

NFE2L1 — Nuclear Factor Erythroid 2-Like 1

Overview

NFE2L1 (Nuclear Factor Erythroid 2-Like 1), also known as Nrf1 (Nuclear factor erythroid 2-related factor 1), is a master transcriptional regulator of the antioxidant response and cellular proteostasis. As a member of the Cap'n'Collar (CNC) basic leucine zipper (bZIP) transcription factor family, NFE2L1 activates genes containing Antioxidant Response Elements (AREs) in their promoters, coordinating a comprehensive defense network against oxidative stress and maintaining protein homeostasis—processes critically implicated in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), and [Huntington's disease](/diseases/huntington-disease). [1] [@sykiotis2010]

Gene Information

NFE2L1 — Nuclear Factor Erythroid 2-Like 1

Overview

NFE2L1 (Nuclear Factor Erythroid 2-Like 1), also known as Nrf1 (Nuclear factor erythroid 2-related factor 1), is a master transcriptional regulator of the antioxidant response and cellular proteostasis. As a member of the Cap'n'Collar (CNC) basic leucine zipper (bZIP) transcription factor family, NFE2L1 activates genes containing Antioxidant Response Elements (AREs) in their promoters, coordinating a comprehensive defense network against oxidative stress and maintaining protein homeostasis—processes critically implicated in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), and [Huntington's disease](/diseases/huntington-disease). [1] [@sykiotis2010]

Gene Information

<div class="infobox infobox-gene"> [@zhang2015]
<table> [@kensler2007]
<tr><th>Symbol</th><td>NFE2L1</td></tr> [@ramachandran2019]
<tr><th>Full Name</th><td>Nuclear Factor Erythroid 2-Like 1</td></tr> [@sankar2015]
<tr><th>Aliases</th><td>Nrf1, NFE2L1, TCF11, HEBP1</td></tr> [@cuadrado2019]
<tr><th>Chromosomal Location</th><td>Chr17p13.3</td></tr> [@dinkovakostova2017]
<tr><th>NCBI Gene ID</th><td>4779</td></tr> [@nakano2018]
<tr><th>Ensembl ID</th><td>ENSG00000100505</td></tr> [@raza2020]
<tr><th>UniProt ID</th><td>Q16186</td></tr>
<tr><th>Protein Class</th><td>Transcription factor, bZIP family</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Protein Structure and Function

Structural Features

The NFE2L1 protein contains several key structural domains: [2]

Molecular Functions

NFE2L1 functions as a transcriptional activator through the following mechanisms:

• DNA Binding: Forms heterodimers with small Maf proteins (MAFF, MAFG, MAFK) and binds to Antioxidant Response Elements (ARE) with the consensus sequence 5'-TGACnnnGC-3'
• Transcriptional Activation: Recruits coactivators including CBP/p300, BRG1, and various histone acetyltransferases
• Target Gene Activation: Regulates over 200 genes involved in antioxidant defense, xenobiotic metabolism, and proteostasis [3]

Key Target Pathways

Antioxidant Response

NFE2L1 activates genes encoding:

• Glutathione Metabolism: [GCLC](/genes/gclc), [GCLM](/genes/gclm), [GSR](/genes/gsr), [GSTA1](/genes/gsta1)
• Thioredoxin System: [TXNRD1](/genes/txnrd1), [TXN](/genes/txn), [TXNRD2](/genes/txnrd2)
• Heme Oxygenase: [HMOX1](/genes/hmox1), [HMOX2](/genes/hmox2)
• Superoxide Dismutases: [SOD1](/genes/sod1), [SOD2](/genes/sod2), [SOD3](/genes/sod3)

Proteostasis Regulation

• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system): [PSMA4](/genes/psma4), [PSMB5](/genes/psmb5), [UBE2D1](/genes/ube2d1)
• [Autophagy](/entities/autophagy): [MAP1LC3B](/genes/map1lc3b), [ATG5](/genes/atg5), [ATG7](/genes/atg7), [SQSTM1](/genes/sqstm1)
• Protein Folding: [DNAJC3](/genes/dnajc3), [DNAJC5](/genes/dnajc5), [HSP70 family](/proteins/hsp70-protein)

Phase II Drug Metabolism

• [Glutathione S-Transferases](/proteins/gst-pi-protein): [GSTA1](/genes/gsta1), [GSTA2](/genes/gsta2), [GSTA4](/genes/gsta4)
• [NAD(P)H:quinone oxidoreductase 1](/proteins/nqo1-protein): [NQO1](/genes/nqo1)
• Uridine diphosphate glucuronosyltransferases: [UGT1A1](/genes/ugt1a1), [UGT2B7](/genes/ugt2b7)

Expression Pattern

Brain Regional Expression

NFE2L1 is widely expressed throughout the [central nervous system](/brain-regions/central-nervous-system), with highest expression in: [4]

• Cerebral [Cortex](/brain-regions/cortex): Particularly layers 2-3 and 5-6, involved in higher cognitive functions
• [Hippocampus](/brain-regions/hippocampus): High expression in [CA1](/cell-types/ca1-pyramidal-neurons), [CA3](/cell-types/ca3-pyramidal-neurons), and [dentate gyrus](/cell-types/dentate-gyrus-granule-cells)
• [Basal Ganglia](/brain-regions/basal-ganglia): Moderate expression in [striatum](/brain-regions/striatum) and [globus pallidus](/brain-regions/globus-pallidus)
• [Substantia Nigra](/brain-regions/substantia-nigra): High expression in dopaminergic [neurons](/entities/neurons)
• [Cerebellum](/brain-regions/cerebellum): Purkinje cells and granule cell layer
• Brainstem: Motor nuclei and reticular formation

Cell Type Specificity

• Neurons: High expression in excitatory glutamatergic neurons and inhibitory GABAergic neurons
• [Astrocytes](/cell-types/astrocytes): Moderate expression, increases in response to oxidative stress
• [Microglia](/cell-types/microglia): Low baseline expression, strongly induced by neuroinflammation
• [Oligodendrocytes](/cell-types/oligodendrocytes): Moderate expression, important for myelin maintenance

Disease Associations

Alzheimer's Disease

NFE2L1 plays a complex role in [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis: [5]

• [Amyloid-beta](/proteins/amyloid-beta) Toxicity: NFE2L1 activation protects against Aβ-induced oxidative stress and neuronal death. Studies show decreased NFE2L1 activity in AD brain tissue, contributing to vulnerability of neurons to oxidative damage.
• [Tau](/proteins/tau) Pathology: NFE2L1 regulates genes that influence tau phosphorylation and aggregation. Dysregulation of NFE2L1 may exacerbate tau pathology through impaired proteostasis.
• Neuroinflammation: NFE2L1 modulates microglial inflammatory responses. Its dysregulation contributes to chronic neuroinflammation in AD.
• Therapeutic Potential: Pharmacologic activation of NFE2L1 (e.g., with CDDO-Me, bardoxolone-methyl) represents a therapeutic strategy for AD to boost endogenous antioxidant defenses. [6]

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), NFE2L1 is critically involved in:

• Dopaminergic Neuron Protection: NFE2L1 activation protects [ventral midbrain dopamine neurons](/cell-types/ventral-midbrain-dopamine-neurons) from oxidative stress-induced death. The [substantia nigra pars compacta](/brain-regions/substantia-nigra) has particularly high oxidative stress burden.
• [Alpha-synuclein](/proteins/alpha-synuclein) Pathogenesis: NFE2L1 regulates autophagy genes that clear α-synuclein aggregates. Impaired NFE2L1 function may contribute to [Lewy body](/diseases/lewy-body-disease) formation.
• Mitochondrial Dysfunction: NFE2L1 target genes include mitochondrial quality control regulators. Its dysfunction exacerbates mitochondrial deficits in PD.
• Neuroprotective Compounds: Sulforaphane and other NFE2L1 activators have shown promise in PD models. [7]

Amyotrophic Lateral Sclerosis (ALS)

In [ALS](/diseases/amyotrophic-lateral-sclerosis), NFE2L1 dysfunction contributes to disease pathogenesis: [8]

• Motor Neuron Vulnerability: NFE2L1 activity is reduced in ALS motor neurons, making them more susceptible to oxidative damage.
• Protein Aggregation: Impaired proteostasis due to NFE2L1 dysfunction may contribute to [TDP-43](/mechanisms/tdp-43-proteinopathy) and SOD1 aggregation.
• Astrocyte Dysfunction: Astrocytic NFE2L1 dysregulation affects support functions for motor neurons.
• Therapeutic Implications: NFE2L1-activating compounds are being investigated for ALS treatment.

Huntington's Disease

In [Huntington's disease](/diseases/huntington-disease):

• Polyglutamine Toxicity: NFE2L1 activation counteracts oxidative stress induced by mutant [huntingtin protein](/proteins/huntingtin).
• Transcriptional Dysregulation: NFE2L1 function is impaired by mutant huntingtin through sequestration of transcription coactivators.
• Mitochondrial Protection: NFE2L1 target genes protect against mitochondrial dysfunction in HD.

Frontotemporal Dementia (FTD)

• TDP-43 Pathology: NFE2L1 dysfunction may contribute to TDP-43 aggregation in FTD.
• Oxidative Stress: Increased oxidative stress in FTD brains associated with reduced NFE2L1 activity.

Signaling Regulation

Activation Pathways

NFE2L1 activity is regulated by multiple signaling pathways:

Negative Regulation

• Keap1-mediated degradation: While Keap1 primarily regulates NFE2L2, it can also sequester NFE2L1.
• Phosphorylation: [GSK-3β](/entities/gsk3-beta) phosphorylation can inhibit NFE2L1 transcriptional activity.
• Acetylation: p300-mediated acetylation can alter NFE2L1 DNA binding and stability.

Therapeutic Implications

Pharmacologic Activation

Several compounds activate NFE2L1 and are being investigated for neurodegenerative diseases:

• CDDO-Me (Bardoxolone Methyl): Potent NFE2L1 activator, in clinical trials for diabetic kidney disease, being explored for AD/PD.
• Sulforaphane: Natural NFE2L1 activator from cruciferous vegetables, shown neuroprotective in animal models.
• Dimethyl fumarate (Tecfidera): FDA-approved for multiple sclerosis, activates NFE2L1 pathway.
• Oltipraz: Synthetic NFE2L1 activator investigated for neuroprotection.

Gene Therapy Approaches

• NFE2L1 Overexpression: Viral vector-mediated NFE2L1 delivery shows promise in preclinical models.
• Small Molecule Activators: Development of brain-penetrant NFE2L1 activators for neurodegenerative diseases.
• Combination Therapy: NFE2L1 activators combined with other neuroprotective strategies.

Interacting Proteins

Key protein interactions include:

• [KEAP1](/genes/keap1): Kelch-like ECH-associated protein 1, negative regulator.
• [MAFF](/genes/maff), [MAFG](/genes/mafg), [MAFK](/genes/mafk): Small Maf dimerization partners.
• [CREBBP](/genes/crebbp) (CBP), [EP300](/genes/ep300): Histone acetyltransferases/coactivators.
• [BRG1](/genes/smarca4): SWI/SNF chromatin remodeling complex.
• [SUMO1](/genes/sumo1): SUMOylation target, regulates nuclear localization.
• [UBB](/genes/ubb) (Ubiquitin): Proteasomal degradation.

Animal Models

Knockout Studies

• Nfe2l1-/- mice: Embryonic lethal, demonstrating essential developmental role.
• Conditional neuronal Nfe2l1 knockout: Show increased oxidative stress, progressive neurodegeneration.
• Astrocyte-specific Nfe2l1 knockout: Impaired neuroprotection, increased vulnerability to toxins.

Transgenic Models

• NFE2L1 overexpression: Protected against MPTP (PD model), Aβ toxicity (AD model), and SOD1G93A (ALS model).
• Human NFE2L1 knock-in: Improved antioxidant response and synaptic function in aging mice.

See Also

• [NFE2L2 (Nrf2) — Related transcription factor](/genes/ran)
• [KEAP1 — Negative regulator of Nrf signaling](/proteins/keap1)
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress)
• [Proteostasis in Neurodegeneration](/diseases/neurodegeneration)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)